Last reviewed · How we verify
NCT03494790: MIMER
Markers of Inflammation and Metabolism in the ER
trial in Acute Infection in 955 participants. Completed in 1 August 2019.
1 August 2019
Quick facts
| Lead sponsor | University of Helsinki |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 955 |
| Start date | 15 December 2017 |
| Primary completion | 1 August 2019 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across Finland |
Conditions studied
- Acute Infection — all drugs for Acute Infection →
- Sepsis — all drugs for Sepsis →
Sponsor
University of Helsinki
Who can join
18 and older, any sex, with Acute Infection or Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adult patients with suspected or confirmed infection and who will be sampled for blood culture will be recruited. Blood samples are collected for the analysis of matrix metalloproteinases (MMP) and their inhibitors. We also aim to analyse metabolic changes and use the samples for analysis of blood lactate, metabolomics, and fibroblast growth factor 21 (FGF-21) as well. The primary aim of the study is to test the performance of MMP-8 in finding severely ill patients who will need treatment in high dependency unit or intensive care. The secondary aim is to study the metabolic changes in acutely ill patients with infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Serum fibroblast growth factor 21 levels after out of hospital cardiac arrest are associated with neurological outcome.
Pekkarinen PT, Skrifvars MB, Lievonen V, Jakkula P, et al · · 2021 · cited 7× · PMID 33436812 · DOI 10.1038/s41598-020-80086-7
Verify or expand the search:
- PubMed search for NCT03494790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Infection
Currently open trials in the same condition.
- NCT05758246 — Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial · Phase 2 · recruiting
- NCT06665542 — A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic T · active not recruiting
Other University of Helsinki trials
Trials by the same sponsor.
- NCT07212361 — Infant Microbiota Restoration With Maternal Microbes · NA · recruiting
- NCT06799988 — NutFinForce: The Impact of Digitally Delivered Lifestyle Performance Medicine Intervention on Defense Performance in Fin · not yet recruiting
- NCT06464003 — Orthodontic Screening in Public Healthcare · recruiting
- NCT06092372 — The Role of Genetics in Weight Loss · NA · completed
- NCT06564675 — Accuracy of EEG Slow Wave Activity in Predicting Favourable Outcome in Patients With Hypoxic Brain Injury - A Substudy o · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03494790 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Helsinki
- Last refreshed: 10 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03494790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing